Related Experiment Video

Updated: Oct 3, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy

A M Senderowicz1

  • 1Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research National Institutes of Health, Building 30, Room 211, 30 Convent Drive, Bethesda, MD 20892-4340, USA.

Cancer Chemotherapy and Biological Response Modifiers
|November 1, 2001
PubMed

Insights

Novel ATP-competitive cyclin-dependent kinase (CDK) inhibitors are being developed to treat cancers caused by CDK hyperactivation. Early clinical trials show promising antitumor activity, but further research is needed to optimize their use.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle.
  • Aberrant CDK activity is implicated in approximately 90% of human neoplasias, often via disruption of the Retinoblastoma (Rb) pathway.

Purpose of the Study:

  • To review the development of novel ATP-competitive CDK inhibitors.
  • To discuss the initial clinical trial findings of flavopiridol and UCN-01.
  • To identify key areas for future research to optimize the therapeutic application of these agents.

Main Methods:

  • Review of preclinical and clinical data on flavopiridol and UCN-01.
  • Analysis of the role of CDKs in cancer development and cell cycle regulation.

Main Results:

  • Flavopiridol and UCN-01 demonstrated promising antitumor activity in early clinical trials.
  • These agents achieved plasma concentrations sufficient for CDK inhibition.
  • Evidence suggests potential for combination therapies and targeted patient selection.

Conclusions:

  • ATP-competitive CDK inhibitors represent a promising new class of anticancer agents.
  • Further studies are required to determine optimal dosing schedules and combinations with existing chemotherapies.
  • Demonstrating CDK modulation in patient tumor samples is essential for validating efficacy and guiding treatment strategies.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.